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Abstract: The therapeutic effect of mesenchymal stromal cells (MSCs) following myocardial infarction (MI) is small. 
This may be due to differences in cellular sources and donor age, route of administration, in vitro cellular manipulations 
and the short time course of follow up in many animal studies. Here, we compared MSCs from two different sources 
(adult bone marrow or Wharton’s jelly from umbilical cord) for their long-term therapeutic effect following MI in a rat 
model to evaluate the effect of donor age. MSCs (or control infusions) were given intravenously 24-48 hr after myocardial 
ischemia (MI) induced by coronary artery ligation. Cardiac function was assessed by ultrasound at time points starting 
from before MSC infusion through 68 weeks after MI. A significant improvement in ejection fraction was seen in animals 
that received MSCs in time points 25 to 31 wks after treatment (p <0.01). These results support previous work that show 
that MSCs can cause improvement in cardiac function and extend that work by showing that the beneficial effects are du-
rable. To investigate MSCs’ cardiac differentiation potential, Wharton’s jelly MSCs were co-cultured with fetal or adult 
bone-derived marrow MSCs. When Wharton’s jelly MSCs were co-cultured with fetal MSCs, and not with adult MSCs, 
myotube structures were observed in two-three days and spontaneous contractions (beating) cells were observed in five-
seven days. The beating structures formed a functional syncytium indicated by coordinated contractions (beating) of inde-
pendent nodes. Taken together, these results suggest that MSCs given 24-48 hr after MI have a significant and durable 
beneficial effect more than 25 weeks after MI and that MSC treatment can home to damaged tissue and improve heart 
function after intravenous infusion 24-48 hrs after MI, and that WJCs may be a useful source for off-the-shelf cellular 
therapy for MI. 
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INTRODUCTION 
 Ischemic heart disease is the primary cause of death 
worldwide [1]. Approximately 7.9 M American adults have 
had a myocardial infarction (MI). MI is caused primarily by 
occlusion of the coronary vessels and results in cardiomyo-
cyte death, scar formation, ventricular remodeling, and even-
tual heart failure. In general, the myocardium does not re-
generate lost cardiomyocytes and pharmacological interven-
tions cannot resurrect dead myocardium. Alternatively, res-
cuing/repairing damaged myocardium by cellular therapy 
offers the possibility of treating MI and preventing heart 
failure.  
 A number of experimental and clinical investigations 
indicate that cellular therapy provides functional improve-
ments to the heart following MI (see [2-4] for review).  
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Cellular therapy following MI using mesenchymal stromal 
cells (MSCs) derived from bone marrow (BM-MSCs) dem-
onstrate long-term cardiac rescue/repair in completed clinical 
trials [4-8]. In contrast, randomized, placebo controlled test-
ing has revealed that mononuclear cell or hematopoietic pro-
genitors do not produce sustained improvement [9-13]. A 
meta-analysis concluded that autologous MSC transplanta-
tion produces a significant modest improvement in cardiac 
function with no additional risks for 3-6 months following 
MI [7]. While experimental and clinical work supports the 
notion of cellular therapy, the effect is small [14].  
 MSC have classically been derived from the bone mar-
row cavity following bone marrow aspiration. Recently, 
MSCs have been found throughout the body including in 
placenta [15-19], adipose tissue [20-23] and umbilical cord 
[24-30]. MSCs can differentiate towards mesodermal linea-
ges, such as fat, cartilage, bone [31-33]; neuroectodermal 
[34, 35], endodermal [36, 37] and cardiac cells [38, 39]. In 
addition, MSCs can contribute to skeletal muscle following 
cell fusion events [40-42]. While MSC differentiation to 
cardiomyocytes is possible, human MSCs have low effi-
ciency for cardiomyogenic differentiation [43, 44]. The age 
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of the MSC donor may impact this observation since MSCs 
derived from younger rats have enhanced potential for car-
diac differentiation [45]. Therefore, we speculated that myo-
cardiogenic and therapeutic potential of MSCs depends upon 
tissue source and upon donor age.  
 Here, we tested whether MSCs derived from the Whar-
ton’s jelly of the umbilical cord (called Wharton’s jelly cells 
or WJCs, below) would have enhanced therapeutic efficacy 
compared with MSCs from adult bone marrow (aBM-MSC) 
for their ability to improve cardiac function following trans-
plantation in the rat MI model. While WJCs did not provide 
better preservation of cardiac function following treatment 
than aBM-MSCs, their sourcing, expansion and banking 
capabilities together suggest that WJCs are superior to aBM-
MSCs as an off-the-shelf treatment for treating MI. In a sim-
plified cardiomyocyte differentiation assay, we found that 
after co-culture of WJCs and fetal BM-MSCs (fBM-MSCs) 
and not after co-culture of WJCs with aBM-MSCs, WJCs 
form simple beating structures (indicating differentiation to 
cardiomyocytes) in 5-7 days and more complex beating 
structures in 7-10 days. Together this preliminary report 
supports the contention MSCs have a durable positive thera-
peutic effect in MI and that WJCs may offer certain advan-
tages over aBM-MSCs as cellular therapy for MI. 
MATERIAL AND METHODS 
Isolation and Expansion of Rat Wharton’s jelly-derived 
MSCs (WJCs) 
 The method to isolate WJCs has been described previ-
ously [46]. Briefly, timed-pregnant female rats were eutha-
nized humanely at 19-21 days post-coitus (DPC) and the 
uterus was removed aseptically to a sterile 150 mm culture 
dish. Inside a biosafety cabinet (BSC), the uterus was opened 
and the umbilical cords were collected (litters varied from 8-
12 pups). The umbilical cord was rinsed with Dulbecco’s 
Phosphate Buffered Saline (DPBS, Invitrogen, cat # 14190-
250) to remove as much blood as possible, and blotted. The 
cord was moved to a single well of a six well dish (8.7 cm2) 
and torn into many small pieces (1 mm or smaller) using 
Dumont #5 forceps. The pieces were allowed to dry in the 
well for about 10 minutes before DMEM with 15% fetal 
bovine serum (FBS) culture medium was added slowly. Over 
the next week, cells were seen migrating out from the cord 
explants onto the culture dish. At passage 0, the cells were 
grown to 85% confluency prior to passage; at the first pas-
sage, the cells from all cords were pooled. To pass, the cells 
were rinsed twice with DPBS followed by 0.05% Tryp-
sin/EDTA for 5 minutes at 37°C. The trypsin was inactivated 
by adding 3 times volumes of growth medium then the cells 
were pelleted by 200g centrifugation for 5 min at room tem-
perature. WJCs were used at passage 5-8 for transplantation 
studies. WJCs were transplanted by intravenous infusion via 
the lateral tail vein or the dorsal vein of the penis (IV, below) 
following labeling with SP-DiI (Invitrogen, D7777) using 
the manufacturer’s protocol. 
Fetal Bone Marrow-Derived MSCs (fBM-MSCs) 
 The pups that were harvested for deriving Wharton’s 
jelly cells (WJCs) were used as fetal bone marrow donors. 
Primary isolation of fetal rat bone marrow was obtained by 
removing the tibia and femur and slicing the bone into small 
pieces. These pieces were incubated in a 50 ml centrifuge 
tube containing 5 ml of 0.25% trypsin. During incubation 
bone pieces were mixed up and down by using 1 ml pipette 
tip. Before centrifugation, the trypsinized tissues were fil-
tered by using a 100 micron filter. Cells were centrifuged at 
200 g for 5 minutes, then red blood cells were lysed using 1 
ml of RBC lysing buffer for 1 minute. The cell suspension 
was pelleted and the cells were washed in DPBS, counted 
and suspended in growth medium (DMEM with 15% FBS). 
Growth medium was changed every other day. At the first 
passage, all cells were pooled together as was done for the 
WJCs. 
Adult Bone marrow-Derived MSCs (aBM-MSCs) 
 The timed-pregnant females which were euthanized to 
isolate WJCs were used as the adult bone marrow donor. The 
fore and hind limbs were rinsed with 70% ethanol, skinned, 
and amputated. Amputated limbs were placed into 150 mm 
sterile culture dish and moved to the BSC. Inside the BSC, 
the long bones were cleaned of muscle and rinsed with 70% 
ethanol. The ends of the bones were removed with bone scis-
sors and the marrow was rinsed from the bones using a 25 ga 
needle attached to a 10 cc syringe containing DMEM. The 
bones were rinsed from both ends with 2-5 ml of medium. 
The medium was collected, filtered through a 100 μm sieve 
and centrifuged. The cell pellet was resuspended in medium 
and counted. BM-MSCs were plated at a density of 10-
15,000 cells/ cm
2 in growth medium (DMEM with 15% 
FBS). The next day, any cells which were not attached were 
removed by a medium change. At passage 0, the cells were 
grown to 80- 85% confluency prior to passage. In contrast to 
the WJCs and fBM-MSCs where all the cells from a litter 
were pooled, aBM-MSCs were processed and handled sepa-
rately. To pass, the cells were rinsed twice with DPBS fol-
lowed by 0.05% Trypsin/EDTA for 5 minutes at 37°C. The 
trypsin was inactivated by adding 3 volumes of growth me-
dium and the cells were pelleted by centrifugation. Adult 
BM-MSCs were used at passage 5-8. Adult BM-MSCs were 
transplanted intravenously via the lateral tail vein or the dor-
sal vein of the penis (IV, below) following labeling with SP-
DiI (Invitrogen, D7777) using the manufacturer’s protocol. 
Co-Culture WJC and BM-MSCs 
 From 7 timed-pregnant rats, isolation of rat umbilical 
cords and fetal bone marrow were obtained at 19-21 DPC. 
Two umbilical cords were dissected into 2-3 mm pieces and 
were placed in a single well (9.6 cm2), after attachment 500 
?l of growth medium was added. In the meantime, the skin 
and muscle were removed from the amputated leg of the 
fetus. Fetal BM-MSC cells were processed as described 
above. WJCs were co-cultured either with adult BM-MSCs 
or with fetal BM-MSCs. BM-MSCs were counted and 
placed at a density of 15,000 cells per cm2 over the explants. 
Then 1.5 ml of warmed growth medium was added to the 
well. The co-cultures were observed daily for 7-10 days. In 
two out of seven isolations, the co-cultures were trypsinized 
and passaged as described above. In one out of seven isola-
tions, fBM-MSCs were labeled with SYTO orange (Molecu-
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lar Probes) following the manufacturer’s recommendations 
prior to co-culture with WJCs. 
Myocardial Infarction 
 Animal protocol was reviewed and approved by the Kan-
sas State University Institutional Animal Care and Use 
Committee (KSU IACUC, approval #2614). MI was created 
by coronary artery ligation using previously described meth-
ods [47]. Briefly, male Sprague Dawley rats 4-6 months of 
age were anesthetized with isoflurane and intubated. The 
thorax was opened at the fourth or fifth intercostal space and 
the heart was exteriorized. The left main coronary artery of 
the rat was ligated with 9-0 nylon and the heart was returned 
to the thorax. The thorax was closed and the animal was ex-
tubated. The animals were closely monitored for 24 hr after 
myocardial infarction. Timed-pregnant rats: Animal protocol 
was reviewed and approved by KSU IACUC (approval # 
3147, 2614). The estrous cycle of female rats was monitored 
by vaginal cytology. When females were in proestrus, they 
were housed overnight with proven stud males. In the morn-
ing, the presence of sperm plugs was taken as proof of suc-
cessful mating and that day was designated day 0 (days post 
coitus, DPC 0). On DPC 19-21, females were euthanized 
humanely and the reproductive tract was removed to harvest 
the umbilical cords and fetal bone marrow as described 
above. In some cases, the bone marrow from the adult fe-
males was isolated from the tibia, femur and humerus as 
described above. MSC transplantation: Animals were anes-
thetized with 2-3% isoflurane in 100% oxygen and placed in 
right lateral recumbence and heart function was measured by 
ultrasound 24-48 hrs after MI surgery. Rats were randomly 
assigned to one of three treatment groups: WJCs, aBM-
MSCs or vehicle (control). The WJC and BM-MSC groups 
received 3-10 x 10
6 cells in 500 μl of phosphate buffered 
saline (PBS) IV. The vehicle group received 500 μl of PBS 
IV. Measurement of cardiac function: At various times fol-
lowing MI (from 24 hrs through 68 weeks), cardiac function 
was assessed by ultrasound. Transthoracic echocardiography 
was performed under isoflurane (2-3% in 100% oxygen) 
anesthesia by a board-certified veterinary cardiologist (MB) 
who was blind to the treatment group (WJCs, BM-MSCs, 
vehicle control). Rats were placed in right lateral recum-
bence and right parasternal long and short axis views of the 
heart were obtained. A Vivid 7 Dimension Cardiovascular 
Ultrasound System BT ’06 (GE Healthcare, Milwaukee, WI, 
USA) equipped with a 11 Mhz sectorial array transducer was 
used for image acquisition. Echocardiographic data were 
collected simultaneously with single-lead ECG and 2 –
dimensional (2D) cineloops including a minimum of 7 con-
secutive heart beats were digitally stored. Only measure-
ments obtained from sinus beats were considered for further 
analyses. From the short axis right parasternal view at the 
level of the papillary muscle the following 2D and M-mode 
variables were measured: left ventricular (LV) internal di-
ameter in diastole (LVDd), LV internal diameter in systole 
(LVDs) from which the fractional shortening was calculated. 
Measurements are reported as the average of 3-5 heart cy-
cles. Left atrial diameter (LA), and aortic root diameter (Ao) 
were measured from the right parasternal short axis view at 
the level of the aortic root. From these, the LA/Ao ratio was 
calculated. Two-dimensional images were also obtained 
from the right parasternal long-axis four-chamber view and 
the right parasternal long-axis five-chamber view. From 
these images color-Doppler interrogation of the mitral and 
aortic valve was performed and calculation of ejection frac-
tion was obtained. Ejection fraction (EF) was calculated with 
the area-length method from the right parasternal four-
chamber view. In most cases, a second-generation ultrasound 
contrast agent BR-38
® was used (see pilot study in supple-
mental information). Ultrasound contrast agents are a sus-
pension of stabilized gaseous microbubbles in saline. The 
gas inside the bubbles is perfluorocarbon gas. The product 
for intravenous infusion was prepared before use by adding 
5ml of saline to the sealed vial followed by manual agitation 
for 30 seconds. BR-38 was infused through a 25G IV cathe-
ter placed in the dorsal vein of the penis. The contrast was 
administered IV as a bolus at the dosage of 0.003 mL/kg 
body weight. In order to avoid hemodynamic effects, a 
minimal volume (less than 0.2 mL including flush) was in-
jected in each animal. MSC Homing In three MI animals and 
one normal animal, the homing of MSCs to the site of pa-
thology was determined. In these cases, 4-10 x106 SP-DiI 
(Invitrogen, D7777) labeled WJCs were injected IV 24 hours 
after MI. Four days later, the animals were euthanized and 
transcardially perfused with heparinized PBS (150 mM so-
dium chloride, 50 mM Sorenson’s phosphate buffer, pH 7.4, 
3 IU heparin per ml) for 5 min to rinse out the blood fol-
lowed by freshly prepared 4% paraformaldehyde in phos-
phate buffer (50 mM Sorenson’s phosphate buffer, pH 7.4) 
for 30 min for fixation. The hearts were removed and cryo-
preserved in 20% sucrose until they equilibrated. Using the 
ligature from the coronary artery ligation and the ischemic 
area for reference, the heart was cut into three blocks: root, 
middle section, and apex. The middle section that contained 
the ischemic zone distal to the ligature was sectioned further 
using a Leitz 1720 cryostat (12 micrometer sections) and air 
dried. The sections were hydrated and the nuclei were coun-
terstained with Hoerscht 24638 (a fluorescent DNA stain), 
followed by being cleared in glycerol and coverslipped; ad-
jacent sections were counterstained with methylene blue or 
hematoxylin and eosin, and coverslipped with DPX mount-
ing medium (Sigma-Aldrich). Sections were observed using 
a Nikon Eclipse microscope fitted with Normaski differential 
contrast and epifluorescence illumination. Images were cap-
tured using a Roper CoolSnap ES using Metamorph V 7 
software. TIFF Images were loaded into Canvas V10 soft-
ware for plate construction. Montages were created by over-
laying adjacent micrographs using tissue landmarks for reg-
istration.  
Data Analysis 
 General linear mixed models were fitted to each of the 
following response variables: "ejection fraction, %", “left 
ventricular end diastolic diameter”, “left ventricular end sys-
tolic diameter”, “fractional shortening, %”, or “left atrial 
diameter – aortic root diameter ratio” measured in rats at 
various times after induction of myocardial infarction. The 
linear predictor in the statistical model used for analysis in-
cluded the fixed effect of cell therapy treatment (control, 
BM-MSCs, WJCs) and "time (in weeks) since induction of 
myocardial infarction", as well as their interaction. When 
evaluating ejection fraction, fractional shortening, left ven-
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tricular end diastolic diameter, left ventricular end systolic 
diameter, “Time” was modeled as a continuous variable to 
accommodate differing times of measurement amongst rats, 
ranging from 0 to 68 weeks after myocardial infarction. 
When evaluating left atrial diameter- aortic root diameter 
ratio, “Time was categorized into three intervals: Time (0-4 
wk), Time (4-8 wks), Time (> 8wks). Also included in the 
model was a random blocking effect of group or litter, and 
its interaction with treatment to recognize the appropriate 
experimental unit for treatment. Kenward Roger's procedure 
was used to estimate degrees of freedom and adjust estimates 
for standard errors.  
 All statistical models were fitted using the MIXED pro-
cedure of SAS (Version 9.2, SAS Institute, Cary, NC). 
Model assumptions were evaluated using externally studen-
tized residuals and were considered to be appropriately met. 
Following significant overall ANOVA, pairwise compari-
sons were conducted using post hoc tests. Note: When mod-
eling “ejection fraction” and “fractional shortening”, one 
observation was excluded from analyses based on a signifi-
cant externally studentized residual, as per Bonferroni testing 
and an identification of influence on the fitted regression 
function. Based upon our previous experience with the myo-
cardial infarction model and the small size of this prelimi-
nary study, significance was set at p < 0.10 for main effects 
and interactions. Data are presented as means ± one standard 
error of the mean (Figs. 3 and 6), or least square mean esti-
mates (Fig. 5). 
RESULTS 
MSC Characterization 
 WJCs and adult or fetal BM-MSCs were characterized 
using three criteria provided by the International Society of 
Cellular Therapy (ISCT) [48]. First, MSCs were evaluated 
by morphology and self-renewal. WJCs and fetal and adult 
BM-MSCs (fBM-MSCs and aBM-MSCs) display typical 
MSC morphology and self-renewal (see Fig. 1). It was noted 
that aBM-MSCs had reduced self-renewal than the other 
groups as indicated by shorter lifespan in culture and more 
limited expansion potential then fBM-MSCs and WJCs. In 
addition, we noted more apoptotic cells and senescent cells 
in aBM-MSCs cultures. Examples of these observations are 
shown in Fig. (1) (compare Fig. 1c with 1a and b). Second, 
fetal bone marrow derived MSCs (fBM-MSCs) displayed 
MSCs surface markers CD90 (60.4% positive), CD73 
(68.2% positive), and CD44 (23.9% positive) and were nega-
tive for hematopoietic surface markers CD34 and CD45 
(Fig. 1d). WJC expressed MSC surface markers CD90 
(88.6% positive), CD73 (46.0% positive), and CD44 (37.8% 
positive) and were negative for hematopoietic surface mark-
ers CD34 (0.0-0.1%) and CD45 (0.0%) (Fig. 1e). Third, 
WJCs and aBM-MSCs differentiated into bone, cartilage and 
fat using standard differentiation protocols and non-
quantitative assessment (Fig. 2a-c). Compared to aBM-
MSCs, WJCs appeared to be more organized collagen fibers 
following chondrogenic differentiation (see Fig. 2a), Both 
WJCs and aBM-MSCs displayed osteogenic differentiation 
(Fig. 2b) and adipogenic differentiation (Fig. 2c). In sum-
mary, both WJCs and BM-MSCs met the minimum defini-
tion of MSCs as provided by the ISCT [32]. 
Cardiogenic Potential Seen After Co-Culture of Bone 
Marrow MSCs and Wharton’s Jelly Cells 
 Twenty-four hours after initiation of co-culture of fetal 
BM-MSCs (fBM-MSCs) and WJCs, cells with tubular or 
cylindrical morphology were observed growing out from 
umbilical cord explant (see arrow in Fig. 2d), at 48-72 hour 
these structures start to elongate and form myotube-like 
structures (see arrows in Fig. 2e). At this time, multiple nu-
clei were observed in a central location (see Fig. 2k and 2l). 
Spontaneous contractions (beating) were observed in indi-
vidual cells between days 5 and 7 (see Fig. 2f and supple-
mental video 1). The beating structures continued to orga-
nize until a functional syncytium was observed by day 10-12 
post-isolation. This was indicated by independent clusters of 
beating cells that demonstrate coordinated contraction (see 
supplemental video 2 and 3). When beating cells were pas-
saged after 10-12 days in co-culture, some cells continued 
beating till passage 2. However, after passage, the cells were 
unable to organize into a functional syncytium (we did not 
observe network of coordinated contraction) and instead 
cells continued to beat as individuals. The present culture 
conditions do not maintain beating cells beyond passage 2. 
As mentioned above, the beating myotubes in passage 0 and 
1 were found to be multinucleated following DAPI staining 
and the tubular structures stained positive for muscle mark-
ers such as MyoD (see Fig. 2j-l). Additionally, the 
multinucleated cells had weak positive staining for connexin 
43 (data not shown). These results are representative from 
six experiments (biological replicates) made using cell de-
rived from either Fischer 344 or Sprague Dawley rats. In one 
experiment, adult BM-MSCs (aBM-MSCs) and WJCs were 
co-cultured; myotubes and beating structures were not ob-
served (see Fig. 2d-f). In one experiment, placenta-derived 
MSCs and WJCs were co-cultured; no beating cells were 
observed (data not shown). In one experiment, fBM-MSCs 
were labeled with SYTO orange prior to co-culture with 
WJCs; this experiment suggested that WJCs, and not fBM-
MSCs, differentiated to the contracting structures (see sup-
plemental Fig. 1). 
Effect of Myocardial Infarction (MI) on Heart Function 
 To evaluate the effect of MI, EF of 4 normal healthy rats 
and 14 rats 24-48 hr after MI was evaluated. As shown in 
Fig. 3, EF was decreased from 82.4 ± 1.7% in normal, 
healthy control animals to 61.9 ± 2.9% 24-48 hrs after MI 
(t(16) = -3.6, p< 0.01).  
Homing of WJCs to Damage 
 To evaluate whether WJCs could be found in the heart 
after IV delivery, 3 x 106 WJCs labeled with SP-DiI were 
infused IV 24-48 hr after MI. To determine specificity of 
WJC homing, a healthy normal animal was injected with the 
same number of labeled WJCs IV. Four days after IV injec-
tion, all animals were sacrificed and the heart was removed, 
blocked, fixed, and cryoprotected. Frozen sections were col-
lected from the peri-infarction zone, or the same region of 
the left ventricle of the normal rat, mounted on slides and 
either cleared and coverslipped for epifluorescent observa-
tion. As shown in Fig. (4), SP-DiI WJCs were found in the 
peri-infarction region in MI animals. In contrast, in normal, 
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healthy control rats that received SP-DiI WJCs IV, no SP-
DiI labeled cells were found in the heart (data not shown). In 
summary, WJCs were found around the damaged regions of 
the heart following IV injection and not in the normal 
healthy heart tissue in a control animal.  
Effect of MSCs on Cardiac Function Following Myocar-
dial Infarction (MI) 
 In this preliminary study, fourteen rats received MI and 
were randomly assigned to three experimental groups: four 
animals were controls and received phosphate buffered sa-
line (PBS) infusion IV, four received WJCs (dose of 10 x106 
cells/ rat), and six rats received aBM-MSCs (dose of 10 x 
106 cells/ rat). The IV infusions were given 24-48 hrs after 
MI and after echocardiography. At various times (2 – 68 wks 
after infusion), heart function was assessed as described in 
Materials and Methods (see also the supplemental informa-
tion). For each measurement, a 1-4 point qualitative value 
was assigned for the quality of the measurement, and each 
measurement was made twice both with and without contrast 
medium. To analyze the data, we used the values with the 
highest quality value, or in the case of a tie, the default was 
contrast-enhanced measurements. This resulted in using con-
trast-enhanced echocardiographic measures in all but two 
measurements.  
Ejection Fraction (EF) 
 A generalized linear mixed model revealed that main 
effects Treatment, Time and Treatment x time interaction 
term were significant. As shown in Fig. (5a), post hoc analy-
sis revealed that there was no evidence for an effect of MSCs 
at times < 25 wk. In contrast, BM-MSC and WJCs signifi-
cantly improved ejection fraction at time points > 25 wks (p 
< 0.01). The significant positive effect of MSCs on EF was 
durable (25 - 32 wk). Furthermore, the MSC treated animals 
survived 52-68 weeks and the controls did not survive longer 
than 32 weeks so we were unable to compare directly the 
cardiac function at those time points. Note that despite ran-
domization of group assignment, post hoc analysis revealed 
that the animals which received MSCs had decreased EF 
compared to vehicle control group at time 0 (57.8 ± 3.1% vs 
72.0 ± 3.4 %, p < 0.05), see Fig. (6).  
Left Atria/ Aortic Root Diameter Ratio (LA/Ao) 
 A generalized linear mixed model revealed that the main 
effects Treatment and Time were significant. As shown in 
Fig. (5b), animals that received WJCs showed decreased 
LA/Ao ratio relative to vehicle controls (t(13.5) = 2.24, p < 
0.09) at all times. In contrast, BM-MSCs were not signifi-
cantly different from vehicle controls. LA/ Ao ratio in-
creased over time after MI in all groups (p< 0.01). Other 
variables In contrast to EF and LA/Ao ratio, no significant 
 
Fig. (1). Morphology and flow cytometry of mesenchymal stromal cells (MSCs). Primary isolation of rat Wharton’s jelly derived-
mesenchymal stromal cells (WJCs, a), fetal and adult bone marrow derived- mesenchmal stromal cells (fBM-MSCs and aBM-MSCs; b and 
c, respectively) derived from a Fischer 344 rat at passage zero. a) WJCs. WJCs show spindle-shape or stellate morphology typical of MSCs. 
Note: the arrow in a) indicates a colony forming unit-fibroblast (CFU-F). b) fBM-MSCs. fBM-MSCs show spindle-shape cells as well as 
round cells (arrows in b). c) aBM-MSCs. aBM-MSCs show flatted morphology, double nuclei, and apoptotic-related changes. aBM-MSC 
culture demonstrated lower expansion potential and early senescence (data not shown). All the pictures were taken 48 hour after isolation.  
(D and E) Flow cytometry of mesenchymal stromal cells derived from adult bone marrow (aBM-MSCs, d) or Wharton’s jelly cells (WJCs, 
e). Flow cytometry was performed on passage 3 cells. Plot shows isotype control staining (open histogram) and specific antibody staining 
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Treatment main effect or Treatment x time interaction effect 
was observed in Fractional Shortening (FS, p = 0.23), left 
ventricular end systolic diameter (LVs, p = 0.61), left ven-
tricular end diastolic diameter (LVd, p = 0.74) (LVd shown 
as representative in Fig. 5c). Consistent with our results for 
EF and LA/Ao, animals from all groups showed a significant 
change in the measurements over time following MI (FS, 
LVs and LVd , p < 0.01).  
 
Fig. (2). a-c) Differentiation induced by incubation in chondrogenic differentiation medium (a), in osteogenic differentiation medium (b) or 
adipogenic differentiation medium (c). a)TOP: Adult bone marrow derived mesenchymal stromal cells (aBM-MSCs) maintained in chondro-
genic differentiation medium (induced; left) or control medium (undifferentiated; right). a) BOTTOM: Wharton’s jelly-derived MSCs (WCs) 
maintained in chondrogenic differentiation medium (induced, left) or control conditions (undifferentiated,right). Cells were differentiated for 
21 days prior to being fixed and stained using Mason’s Trichrome staining for collagen detection. Note that BM-MSCs showpositive staining 
(light green), which indicates the presence of collagen. Note that WJCs maintained in chondrogenic medium (left) displayed fascicules of 
fibrilar material staining positive for collagen. B) TOP: BM-MSCs maintained in osteogenic differentiation medium (left, induced) or control 
(undifferentiated) medium (right, control). b) BOTTOM: WJCs maintained in osteogenic differentiation medium (left) or control (undifferen-
tiated) conditions (right). Cells were differentiated for 21 days prior to being fixed and von Kossa staining. Note the dark crystalline staining 
in the differentiated cells indicating deposition of calcium matrix. C) TOP: Adipogenic differentiation of BM-MSCs. Cells were cultured 
under adipogenic differentiation conditions (left, induced) or under standard culture (control) medium (right) for 21 days. C) BOTTOM: 
Adipogenic differentiation of WJCs. Adipogeneic conditions (induced) or standard culture conditions (control) for 21 days. Oil Red-O was 
used to stain lipids and hematoxylin for staining nuclei. Differentiation to adipogenic lineage induced small lipid droplets which stained posi-
tive with oil red-O to accumulate in the cytoplasm. d-i) Co-culture of rat Wharton’s jelly cells (WJCs) with bone marrow derived mesen-
chymal stromal cells (BM-MSCs). Co-culture of WJCs with fetal BM-MSCs (fBM-MSC, d-f, j-l) or adult BM-MSCs (aBM-MSCs, g-i). 
Primary isolation and co-culture of WJCs with fBM-MSCs. d) Day 1 of co-culture. Note that a cylindrical structure (arrow in a) is observed 
growing from the umbilical cord explant (dashed line in a outlines umbilical cord explant). e) Day 4 of co-culture. Note that the cylindrical 
structure has enlarged and multiple nucleiare observed in the central portion. f) Day 7 of co-culture. Beating myotubes can be seen (beating 
structures are indicated by arrows). Note that multiple fibers are organized in parallel. g- i) Primary isolation and co-culture of WJCs and 
aBM-MSCs. g) Day 1 of co-culture. h) Day 4 of co-culture; and i) Day 7 of co-culture. Neither beating structures nor cylindrical structures 
were observed. j-l Immunocytochemistry of WJCs co-cultured with fBM-MSCs. j) Phase contrast micrograph of WJCs with fBM-MSCs, 
dashed line indicates the boundary of rat umbilical cord explant. Note that multinucleated, myotube-like strucutures are observed growing 
from the explant. k) Immunocytochemical staining for MyoD (visualized using Alexa 594 secondary antibody) counterstained with 4',6-
diamidino-2-phenylindole (DAPI, a fluorescent DNA stain) revealed positive MyoD staining in both myotube-like structures, as well as in 
smaller fusiform or round uninucleated cells present in the center of the explant and periphery l) Merge fluorescent markers with correspond-
ing phase contrast to emphazise Myo D distribution associated with tube structures radiating from explant. 
Induced Control
c
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 We did not perform survival analysis due to the small 
number of animals in our preliminary study.  
DISCUSSION 
 The major findings in the present investigation were that 
1) WJCs home specifically to damaged myocardium after IV 
injection, 2) MSCs from adult bone marrow and from Whar-
ton’s jelly had a beneficial effect on the EF > 25 wk follow-
ing MI and these effects are durable, extending from 25-32 
wks after MI, and 3) 4) co-culture of WJCs with fetal BM-
MSCs, and not co-culture of WJCs with adult MSCs, in-
duced the formation of myotube structures which contract 
rhythmically (beat) and formed a functional syncytium 
within one week.  
 To our knowledge, this is the first report of WJCs iso-
lated from rats. Perhaps this is because the explant method is 
needed to isolate rat WJCs since enzymatic digestion of the 
cord is unreliable at establishing WJC cultures from rat um-
bilical cord [30]. In terms of morphology and self-renewal 
potential WJCs were more similar to fBM-MSCs than to 
aBM-MSCs (see Fig. 1). Both WJCs and BM-MSCs express 
CD73, CD90 and CD44. However, the surface expression of 
CD90 and CD44 reported here might be lower than for 
WJCs from human origin [30]. WJCs were multipotent in the 
qualitative assays performed in the present investigation; 
WJCs and BM-MSCs differentiate to bone, cartilage and fat. 
We suggest that there might be differences in the differentia-
tion potential between WJCs and aBM-MSCs that more sen-
sitive, quantitative assays might elucidate. In agreement with 
our differentiation findings, human WJCs produce more col-
lagen than aBM-MSCs when placed under chondrogenic 
differentiation [33]. In contrast to our observation of rat 
WJCs differentiation to bone, human WJCs produce dense 
bone nodules, similar to aBM-MSCs [20]. Therefore, based 
upon their self-renewal and morphology, surface marker 
expression, and in vitro multipotency rat WJCs meet the 
definition of MSCs as defined by the ISCT [32]. 
 There are a number of clinical trials evaluating MSCs as 
regenerative therapy following MI (90 clinical trials were 
found on the CLINICALTRIAL.GOV website using the 
search terms: “myocardial infarction” and “MSC” on 25 Sept 
2012). To date, the experimental data suggests that MSCs 
from younger animals will provide greater benefit than those 
from older animals for treating MI [33-35]. A meta-analysis 
found that following intracoronary infusion of autologous 
BM-MSCs, there is a small, significant improvement in ejec-
tion fraction between 3 and 6 months with no enhanced risk 
[8]. Like intracoronary infusion of MSCs, IV infusion of 
BM-MSCs results in MSC homing to the heart, improves left 
ventricular function and decreases infarct size [49, 50]. We 
found a significant improvement in ejection fraction at 25 – 
32 wks following IV infusion of aBM-MSCs or WJCs. Fur-
thermore, the animals that received MSCs survived until till 
68 weeks post-MI. In contrast, the vehicle control animals 
died < 32 weeks after MI. Similar to our observation using 
rat WJCs, Wu et al. tested human WJCs in a rat MI model 
and found positive effects on heart function in the 2-4 week 
survival period following direct transplantation into the heart 
[51]. At four weeks after transplantation, Wu et al. found 
engrafted human WJCs that stained with cardiac troponin T, 
suggesting that human WJCs show engraftment and in vivo 
cardiomyogenic potential [51]. Together with our data, these 
findings support the notion that MSCs given IV can possibly 
improve cardiac function following MI. 
 A number of mechanisms have been proposed for the 
improvement in cardiac function following MSC treatment 
(see review [52-55]). First, MSCs have a well-documented 
immune suppressive effect on activated T cell proliferation 
[30, 56-58]. The thought is that immune modulation by 
MSCs would decrease immune-mediated cardiomyocyte 
losses following MI and reduce the size of the scar [59]. 
Second, MSCs have an angiogenic / neovascularization ef-
fect and generation of new vessels in the peri-infarct region 
may stem cardiomyocyte loss and aid in functional recovery 
following MI [51, 59-65]. Third, MSCs, especially MSCs 
 
Fig. (3). Myocardial infarction (MI) decreases heart function. Twenty-four to 48 hours after MI, rats were lightly anesthetized for restraint 
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from a young donor, may have an enhanced cardiomyogenic 
potential in vitro [38, 44, 45, 66-71] and perhaps in vivo 
[51]. This mechanism suggests that donor cells form new 
cardiomyocytes to assist with heart function. Care must be 
taken in interpreting these data since MSCs might fuse with 
cardiomyocytes, and appear to be new cardiomyocytes [72, 
73]. Fourth, MSCs produce a number of cytokines and 
chemokines which may reduce cardiomyocyte loss or rescue 
damaged cardiomyocytes from degeneration. This would 
suggest that MSCs might work at a distance to produce a 
beneficial effect following MI, and would not require MSCs 
to engraft in the heart to produce a positive effect. Note that 
MSCs “working at a distance” mechanism has been demon-
strated following cornea damage; specifically the underlying 
mechanism was shown to be mediated by the anti-
inflammatory protein TNF-? stimulated gene / protein 6 re-
leased by MSCs [54]. Further work is needed to determine 
whether different types of MSCs have different functional 
benefits following MI, as has been suggested from work us-
ing smooth muscle cells to treat MI [65], and to determine 
which mechanism or mechanisms are responsible for our 
observations. 
Cardiomyogenic Potential of MSC 
 The ISCT defines MSCs as cells that have a certain mor-
phology and self-renew, express certain surface markers, and 
differentiate along mesoderm lineages such as bone, carti-
lage and fat [32). MSCs, especially MSCs from young 
sources, have the potential to differentiate into neural linea-
ges [74, 75] and myocardial lineage. Here, we demonstrated 
cardiomyogenic differentiation following co-culture of 
WJCs with fBM-MSC. Previous methods used to induce 
MSCs to cardiomyogenic differentiation include exposure to 
DNA methyltransferase inhibitor such as 5-azacytidine [44, 
51, 70, 71, 76, 77], exposure to growth factors/ cytokines 
such as bone morphogenic protein 2, fibroblast growth factor 
2, insulin-like growth factor 1 [45, 78], exposure to TGF-? 
[79], or by co-culturing with cardiac myocytes [80-83]. In 
these methods, young MSCs, and to a lesser extent old 
MSCs differentiate into cardiomytocytes or pre-
cardiomyocytes over 2-3 wks or up to 30 days and these 
methods sometimes result in beating cells (such as shown in 
supplemental video 1). Infrequently did these methods pro-
duce coordinating beating as shown here in supplemental 
video 2 and 3.  
 In contrast, in the present paper, our method induces 
rapid cardiogenic differentiation that may be more rapid than 
previous methods. By tracking migration of cells from the 
umbilical cord explant, we believe that the cardiogenic cells 
derive from WJCs (see supplemental Fig. 1), but more work 
is needed to support this conjecture. Our data indicates that 
the age of the donor impacts the MSC’s ability to undergo 
cardiogenic differentiation since WJC and fBM-MSC co-
culture resulted in cardiomyogenic differentiation and syn-
 
Fig. (4). Wharton’s jelly cells (WJCs) home to the peri-infarct region following myocardial infarction (MI). Twenty-four hours after MI, rats 
received 3 x 106 Sp-DiI labeled WJCs by intravenous infusion through the dorsal vein of the penis. Four days later the animal was euthanized 
and the tissue was prepared as described in the Material and Methods. A. Tissue stained with hematoxylin and eosin showing the peri-infact 
region. B. Section adjacent to A stained with Hoerscht 24638 (a fluorescent DNA stain), cleared in xylenes and coverslipped for observation 
using epifluorescence. The heart outline is shown in the line drawing with box insets with circles the location of WJC clusters in the adjacent 
photomicrographs. Note that clusters of SP-DiI stained cells were located in the peri-infarct region. No SP-DiI labeled cells were found in the 
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cytium formation, and co-culture of WJC with aBM-MSC 
did not. In support of our observations, Asumda and Chase 
showed that donor age impacts MSC plasticity and cardio-
genic differentiation [45]. Similarly, in support of our obser-
vations, La Rocca et al. showed that WJCs may express the 
transcription factor GATA-4 [84]; GATA-4 is a critical tran-
scription factor for cardiomyogenic differentiation [66]. 
Since we demonstrate that WJCs can undergo in vitro car-
diomyogenic differentiation, our data support Wu et al.’s 
observation that human WJCs might assist recovery follow-
ing MI by formation of cardiomyocytes in vivo [51]. We 
were able to pass differentiated cardiogenic cells twice and 
retain a few beating cells; however, following passage there 
was loss of the coordinated contracting ensemble (the passed 
cells could not re-form this ensemble). In the future, refine-
ments to growth medium, substrate or other culture variables 
are needed to enhance the efficiency of cardiomyogenic dif-
ferentiation, and enable re-establishment of higher-order 
organization between the contracting cells.  
Are WJCs Superior to BM-MSCs for Cellular Therapy? 
 Several lines of evidence suggest that WJCs have certain 
advantages as a cell therapy for MI over aBM-MSC or fBM-
MSCs. First, in terms of generation of a clinical dose, in vi-
 
Fig. (5). Effect of mesenchymal stromal cell (MSC) treatment on heart function following myocardial infarction (MI). At various time peri-
ods (just before IV infusion of cells or control (time 0), and 2-32 weeks after MI), rats in all three experimental groups had echocardio-
graphic assessment of cardiac function with and without contrast medium while under light anesthetic restraint. a) Ejection fraction. Ejection 
fraction in the control group decreased continuously until either death due to heart failure or termination at the end of the experiment. The 
decrease in ejection fraction in the two groups that received MSCs, either Wharton’s jelly cells (WJCs) or adult bone marrow derived mesen-
chymal stromal cells (BM-MSCs), was significantly less than the control group at time points > 25 wk. While there was no significant differ-
ence between the WJCs or the BM-MSC group at time 0. b) Left ventricle to aorta outlet ratio (LA/Ao). In the WJC group, and not in the 
BM-MSC group, the LA/Ao ratio was significantly different from control animals. In all groups, the LA/Ao ratio significantly increased over 
time following MI. c) Left ventricle end diastolic diameter (LVd). Other variables measured including LVd, left ventricular systolic diame-
ter, fractional shortening, etc were not significantly different between experimental groups (LVd is shown as an example). LVd, left ventricu-
lar end systolic diameter, and fractional shortening showed increases over time (as is shown for LVd here). 
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tro expansion is a critical variable to consider. Previous work 
demonstrates that WJCs expand more rapidly and to a 
greater extent than aBM-MSCs prior to senescence [20, 34]. 
Similarly, as the donor age increases, more difficulty is 
noted in establishing aBM-MSCs [62]. Here, we observed a 
similar pattern with rat fetal and adult MSCs. In a pilot 
study, we tried to establish BM-MSCs from 14 month old 
rats (old MSCs, data not shown). Compared to the aBM-
MSCs used here, old MSCs could not be established in cul-
ture and displayed a flattened, stellate morphology (YL and 
MLW, unpublished observation). In support of that observa-
tion, Asumda and Chase compared MSCs from 4 month and 
14 month old rats and noted the flattened morphology and 
loss of tri-lineage differentiation potential in the older MSCs 
[45]. In addition to greater expansion potential, WJCs have 
greater colony forming unit- fibroblast (CFU-F) frequency 
than adult bone marrow-derived MSCs [23]. CFU-F is an 
indicator of self-renewal potential, a defining property of 
stem cells. In our investigation, co-culture of fBM-MSCs 
with WJCs produced rapid cardiomyogenic differentiation. 
In contrast, co-culture of aBM-MSC with WJCs did not pro-
duce cardiomyogenic differentiation. While others have re-
ported that younger MSCs have cardiogenic differentiation 
potential superior to older MSCs [45, 65], our interpretation 
is that fBM-MSCs, through direct contact or via paracrine 
factors, can induce cardiomyogenic differentiation of WJCs. 
Together, these data suggest that WJCs have a broader dif-
ferentiation potential than MSCs from old animals. For all 
these reasons, we suggest that WJCs may be a more advan-
tageous adjunct for MI cell therapy. 
 In the present study, we compared aBM-MSCs and WJCs 
to test our hypothesis that WJCs would be superior for 
treatment following MI. A durable improvement in EF fol-
lowing MSC treatment was noted for both cell sources 25-32 
weeks post MI. We found no conclusive difference between 
aBM-MSCs and WJCs as therapeutic cell sources. Based 
upon their impact on cardiac physiology, there is no clear 
advantage between the two MSC sources found in this pre-
liminary study. However, WJCs have other features that 
need to be considered for their use as a therapy for treating 
MI. First, WJCs are collected safely, easily and painlessly at 
birth for later use as an allogeneic cell therapy. This is in 
contrast to fetal BM-MSCs or adult BM-MSCs, which re-
quire painful or invasive procedures to obtain. Fetal BM-
MSCs are rare and more controversial in their tissue source 
compared to discard umbilical cords, the source of WJCs. 
Second, WJCs can be readily expanded and cryopreserved to 
be ready to use an off-the-shelf allogeneic cellular therapy. 
Therefore, given that WJCs infused IV in the 24-48 hr win-
dow following MI home to sites of tissue damage and pro-
duce long-term positive effect upon cardiac function, we 
propose that IV WJCs may be a safe and effective off-the-
shelf cellular therapy for treating MI. We note that intra-
coronary human WJCs have been evaluated in humans with 
acute myocardial infarction (CLINICALTRIALS.GOV iden-
tifier: NCT01291329). To date, the study results have not 
been posted. Taken together, there are suggestions that WJCs 
are worthy of further investigation. 
Delivery of MSCs 
 There are differences of opinion about therapeutic cell 
delivery for treating MI (for review see [85, 86]). Clearly, 
intracoronary or direct injection into the peri-infarction zone 
is an effective and efficient means to deliver cells to the heart 
[7], it is also the most invasive means of delivery. We dem-
onstrated that WJCs home to damaged myocardial tissue 
following IV infusion: WJCs were found in the peri-
infarction zone following IV infusion and WJCs and aBM-
MSCs had a positive, durable functional effect 25-32 wks 
following MI. These results suggest that a therapeutic dose 
of MSCs has been delivered non-invasively. In support of 
this observation, others have shown that IV delivery of 
MSCs have positive effects following MI in rodent and 
 
Fig. (6). Comparison of ejection fraction at time 0 between vehicle group and group that received mesenchymal stromal cells (MSCs). We 
assumed that randomized assignment to the experimental groups would result in ejection fraction being not significantly different between 
the vehicle group and group that received MSCs at time 0. Note: that ejection fraction measured at time 0 was made before intravenous infu-
sion of MSCs or vehicle. When compared to the vehicle group, the group that received MSCs (BM-MSCs and WJCs) had a significantly 
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swine models [49, 87]. Additionally, MSCs have therapeutic 
effects without significant homing to the damaged tissue via 
immune modulation actions such as via tumor necrosis factor 
? induced protein 6 (TSG-6), as is seen following corneal 
scarification [88] or following MI [89]. In terms of patient 
safety, IV delivery might improve the safety margin for cel-
lular therapy. Further work is needed to confirm whether a 
dose-response relationship is found following IV MSC ther-
apy and further work is needed determine whether IV TSG-6 
works for treating MI in humans, mooting the point of direct 
or intracoronary injection. It may be necessary to demon-
strate directly that the intracoronary delivery of TSG-6 or 
MSCs outweighs the safety and less invasive nature of IV 
delivery. 
 The timing of MSC delivery is likely to be a critical fac-
tor for efficacy of cell therapy. We delivered MSCs 24-48 
hrs after MI. The non-invasive IV treatment lends itself to 
multiple doses if necessary and beneficial without incurring 
additional risk to an already damaged heart. Further work is 
necessary to experimentally support these notions. 
Assessing Heart Function Following Myocardial Infarc-
tion 
 We found that MSCs had a significant, positive effect on 
EF at 25 wks and that positive effects lasted to 32 wks (and 
perhaps as long as 68 wks after MI). In contrast, the LA/Ao 
ratio data showed a significant effect for WJCs, and no sig-
nificant effect for BM-MSCs, compared to vehicle control. 
LA/Ao root diameter ratio is a measure of left atrial en-
largement that has been associated to both heart failure and 
increased risk of death in humans and animals [90, 91]. 
While these data suggest a positive effect of WJC therapy 
upon some variables of cardiac function following MI, they 
do not clearly discriminate whether WJCs were more effec-
tive than aBM-MSCs. Similar to our observations, Wu et al. 
used echocardiography to assess the effect of human WJCs 
in the four weeks following MI [51]. Wu et al. found a sig-
nificant improvement at both the two week and four week 
time point following MI compared to the control group. In 
contrast to the report by Wu et al., our MI rats demonstrated 
a decline in cardiac function (ejection fraction and other 
functional variables) over time (see Fig. 5). Our vehicle con-
trol rats showed progressive loss of cardiac function and left 
atrial enlargement. All the vehicle control rats died < 32 wks 
after MI. Our data suggest that MSC treatment might de-
crease or prevent the progressive loss of function following 
MI.  
 In this preliminary study, a small number of animals 
were assigned per group. Despite the small group size, we 
detected a significant impact of MSC therapy. Since rats 
initially compensate well following MI, and over time, more 
and more rats enter decompensated heart failure and die, this 
preliminary study should be followed with a larger study that 
evaluates in more depth the effect of MSCs on survival and 
provide a finer grain analysis of the components of cardiac 
function following MSC treatment.  
 In our study, post hoc analysis revealed that the animals 
that received MSCs might have had larger initial MIs than 
the vehicle control group (see Fig. 6), despite our randomiza-
tion of group assignment. This observation suggests that 
MSCs might have had larger impact on heart function. 
Again, this suggests that this preliminary report should be 
followed on with study with larger group sizes to improve 
the statistical power and show more conclusively whether 
MSC treatment improved survival following MI and would 
clarify whether aBM-MSCs or WJCs are significantly differ-
ent. 
 In conclusion, several lines of evidence presented suggest 
that IV MSCs might provide a positive, durable benefit when 
given in the 24-48 hour window following myocardial in-
farction. We found that the benefit of MSCs became signifi-
cant 25 wks after treatment and this was probably due to the 
progression nature of the MI injury in the control animals 
and the stemming of the progression in the MSC groups. We 
provided evidence that adult BM-MSCs and WJCs were ef-
fective on one measure of cardiac function (EF). We suggest 
that IV WJCs might be more advantageous than aBM-MSCs 
as an allogeneic, off-the-shelf therapy for MI. We found that 
co-culture of WJCs with fetal BM-MSCs induced rapid and 
robust differentiation along the cardiomyogenic lineage. The 
co-culture produced ensembles with coordinated contraction 
over the course of one week. Taken together, these data 
demonstrate that cardiac lineage development may be greatly 
improved by co-culturing MSCs from younger donors and 
suggest that MSCs from younger donors should be consid-
ered for regenerative therapy. 
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